Category survey

MULTISCALE ANALYSIS OF SENSORY-MOTOR CORTICAL GATING IN BEHAVING MICE Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Mechanisms of PhIP-induced dopaminergic neurotoxicity Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

PROTEASOME AND PARKIN AS DRUG TARGETS AGAINST METHAMPHETAMINE TOXICITY Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Understanding the role of MAPT in Parkinsonian disorders Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Intrinsic Activity and Cognition in Parkinson Disease Assessed by Simultaneous fMRI/EEG Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

RANTES and Eotaxin: New players in PD progression Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

ROLE OF CHAIN LENGTH AND SEQUENCE CONTEXTS ON POLYGLUTAMINE OLIGOMERIZATION Investments > €500k United States of America Huntington’s disease 2016    

Robust rare event simulation for protein folding and disease-related aggregation Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Investigating disease Mechanisms in C9orf72-linked ALS/FTD Investments > €500k United States of America Motor neurone diseases 2016    

Deranged calcium signaling and polyglutamine expansion disorders Investments > €500k United States of America Huntington’s disease 2016    

Neuron death in Parkinsons disease: The role of Trib3 Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Novel genetic determinants of the neuromuscular SMA phenotype Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Regulation of the oligodendroglial accumulation of alpha-synuclein in Multiple System Atrophy Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Dynamin-related protein 1, neurodegeneration and Huntingtons disease Investments > €500k United States of America Huntington’s disease 2016    

TDP-43 and Mitochondrial Dysfunction in ALS Investments > €500k United States of America Motor neurone diseases 2016    

Mechanisms of HIPK2 in neurodegeneration Investments > €500k United States of America Motor neurone diseases 2016    

Mechanisms of rotenone-induced neuroinflammation and Parkinsonism in aging mice Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Regulation of Mitochondrial Autophagy by Parkin Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Huntingtin proline-rich region modulation of Huntingtons disease pathogenesis Investments > €500k United States of America Huntington’s disease 2016    

Prefrontal D1 signaling and cognitive symptoms of Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis Investments > €500k United States of America Motor neurone diseases 2016    

Mechanisms of Central Synaptic Dysfunction in SMA Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Pathogenic mechanisms of gene-environment interactions in Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Understanding SOD1 Kinetics in Amyotrophic Lateral Sclerosis Investments > €500k United States of America Motor neurone diseases 2016    

Role of LRRK2 in dopaminergic transmission Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Propagation of Lewy pathology in Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Role of ABHD6 in 2-AG Signaling Investments > €500k United States of America Huntington’s disease 2016    

Biology of Native Alpha-Synuclein Tetramers in Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Modeling synaptic vesicles: how does alpha-Synuclein inhibit fusion? Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Complement-Microglia Interaction in Synaptic Loss and Neurodegeneration in HD Investments > €500k United States of America Huntington’s disease 2016    

Huntingtons disease: a novel developmental oligodendrogliopathy Investments > €500k United States of America Huntington’s disease 2016    

Structure of Triplet Repeat mRNA in Neurodegenerative Disease Investments > €500k United States of America Huntington’s disease 2016    

Unbiased Approaches to Novel Biomarker Discovery in Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Neuroregulatory Mechanisms of PIAS1 and Implications for Huntingtons Disease Investments > €500k United States of America Huntington’s disease 2016    

Treatment of ALS based on transplantation of glial restricted progenitors Investments > €500k United States of America Motor neurone diseases 2016    

Dopamine modulation of synaptic plasticity and integration in the striatum Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Gene-Neurotoxicant Interactions in Huntington Disease Investments > €500k United States of America Huntington’s disease 2016    

Glucocerebrosidase Biology and Its Role in Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Dopamine-Induced Striatal Synaptic Plasticity Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Protein variants as blood based biomarkers for diagnosing and staging AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

The COPA vesicle protein and pathogenesis of spinal muscular atrophy Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Etiological Linkage of DNA Damage/Repair Deficiency in Neurodegenerative Diseases Investments > €500k United States of America Motor neurone diseases 2016    

Animal Models for Studying Human Frontotemporal Dementia Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Investigating a Toxic Gain-of-Interaction Between FUS/TLS & Stress Granules Investments > €500k United States of America Motor neurone diseases 2016    

Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions Investments > €500k United States of America Motor neurone diseases 2016    

Using reporter human iPS cells to study fate, function and Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Vesicular modulation of dopamine neuron toxicity Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Redesign Rat Model for ALS Research Investments > €500k United States of America Motor neurone diseases 2016    

Intact Circuit Assessment of Aging Dopamine Neurons vis Optogenetics and CLARITY Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

NAD metabolsim and mitochondrial dysfunction in ALS models Investments > €500k United States of America Motor neurone diseases 2016